On Oct. 6, 2022, Merck announced data from two real-world evidence studies evaluating LAGEVRIOï¾™ (molnupiravir), an investigational oral…
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
On Sept. 27, 2022, the National Institutes of Health announced that a large international study had confirmed the…
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
On Sept. 28, 2022, Pfizer and BioNTech announced they have completed a submission to the U.S. Food and…
On Supt. 22, 2022, Pfizer announced an agreement to supply up to six million treatment courses of its…
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use…
On Sept. 15, 2022, Gilead Sciences announced updates to the World Health Organizationï¾’s Therapeutics and COVID-19: living guideline,…
On Sept. 13, 2022, Novavax and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer…
On Sept. 2, 2022, Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, had expanded its temporary…
On Sept. 2, 2022, Novavax announced that the World Health Organization had approved a variation to allow SK…
On Sept. 1, 2022, Novavax announced that Nuvaxovidï¾™ (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional marketing…
On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency in the United Kingdom…
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
On Aug. 23, 2022, Moderna announced that it has completed its submission to the U.S. Food and Drug…
On Aug. 23, 2022, Pfizer and BioNTech announced updated efficacy results from a Phase 2/3 trial evaluating a…
On Aug. 22, 2022, Pfizer and BioNTech announced they had completed a submission to the U.S. Food and…
On Aug. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received expanded emergency use…
On Aug. 18, 2022, Novavax announced that New Zealand’s Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373)…
On Aug. 15, 2022, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK…
On Aug. 12, 2022, Novavax announced that partner, SK bioscience, had received a Post Approval Change Application approval…
On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission to convert contractually…
On Aug. 4, 2022, Novavax announced the initiation of its Phase 2b/3 Hummingbird global clinical trial. The trial…
On Jul. 29, 2022, The U.S. Department of Health and Human Services, in collaboration with the U.S. Department…
On Jul. 29, 2022, Moderna announced that the U.S. government has secured 66 million doses of a Moderna…
On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
On Jul. 26, 2022, Novavax announced that the Australian Therapeutic Goods Agency had granted expanded approval for provisional…
On Jul. 26, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had received expanded manufacturing and marketing approval…